Price
Financials
Standalone, Rs crore| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 314 | 298 | 294 | 347 | 361 | 342 | 353 | 422 |
| Expenses | 247 | 228 | 239 | 277 | 283 | 259 | 291 | 329 |
| Operating Profit | 67 | 69 | 54 | 70 | 78 | 83 | 62 | 93 |
| OPM % | 21% | 23% | 18% | 20% | 22% | 24% | 18% | 22% |
| Other Income | 2 | 1 | 1 | 2 | 2 | -17 | 4 | 3 |
| Interest | 3 | 2 | 2 | 2 | 2 | 2 | 1 | 3 |
| Depreciation | 9 | 10 | 10 | 9 | 9 | 9 | 10 | 13 |
| Profit before tax | 57 | 58 | 43 | 61 | 70 | 55 | 54 | 80 |
| Tax % | 25% | 23% | 28% | 24% | 25% | 25% | 17% | 25% |
| Net Profit | 43 | 45 | 31 | 46 | 52 | 41 | 45 | 60 |
| EPS in Rs | 7.03 | 7.32 | 5.12 | 7.59 | 8.53 | 6.74 | 7.37 | 9.83 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 509 | 601 | 576 | 617 | 884 | 1,014 | 1,196 | 1,403 | 1,479 |
| Expenses | 444 | 509 | 471 | 600 | 756 | 859 | 956 | 1,109 | 1,162 |
| Operating Profit | 66 | 93 | 105 | 18 | 128 | 156 | 241 | 294 | 317 |
| OPM % | 13% | 15% | 18% | 2.9% | 14% | 15% | 20% | 21% | 21% |
| Other Income | 3 | 3 | 5 | 7 | 7 | 5 | 5 | -9 | -7 |
| Interest | 1 | 2 | 2 | 5 | 4 | 14 | 11 | 7 | 8 |
| Depreciation | 14 | 16 | 16 | 20 | 20 | 28 | 37 | 38 | 42 |
| Profit before tax | 54 | 77 | 92 | -1 | 111 | 118 | 198 | 240 | 260 |
| Tax % | 35% | 24% | 24% | -49% | 23% | 24% | 25% | 23% | |
| Net Profit | 35 | 59 | 70 | -0 | 85 | 90 | 149 | 185 | 199 |
| EPS in Rs | 74.85 | 126.70 | 150.72 | -0.08 | 13.85 | 14.80 | 24.37 | 30.22 | 32.47 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 20% | 25% | 30% | 33% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | 19% | 17% | 18% | ||
| Compounded Profit Growth | % | 23% | 33% | 28% | ||
| Stock Price CAGR | % | % | % | % | ||
| Return on Equity | % | 22% | 26% | 30% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 51 | 61 | 61 | 61 | 61 |
| Reserves | 204 | 263 | 333 | 270 | 347 | 419 | 545 | 685 |
| Borrowings | 13 | 47 | 50 | 34 | 28 | 159 | 86 | 165 |
| Other Liabilities | 71 | 94 | 144 | 157 | 159 | 191 | 237 | 293 |
| Total Liabilities | 293 | 408 | 532 | 511 | 595 | 830 | 929 | 1,204 |
| Fixed Assets | 80 | 81 | 164 | 162 | 185 | 384 | 370 | 554 |
| CWIP | 4 | 42 | 0 | 14 | 65 | 121 | 186 | 143 |
| Investments | 9 | 7 | 37 | 14 | 31 | 25 | 25 | 25 |
| Other Assets | 200 | 278 | 330 | 321 | 314 | 301 | 348 | 482 |
| Total Assets | 293 | 408 | 532 | 511 | 595 | 830 | 929 | 1,204 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 19 | 43 | 79 | 98 | 103 | 157 | 190 | 229 |
| Cash from Investing Activity | -23 | -50 | -102 | -66 | -50 | -267 | -84 | -256 |
| Cash from Financing Activity | 4 | 30 | 0 | -30 | -45 | 99 | -107 | 25 |
| Net Cash Flow | -1 | 23 | -23 | 2 | 8 | -11 | 0 | -1 |
| Free Cash Flow | 19 | 1 | 6 | 64 | 9 | -129 | 99 | 56 |
| CFO/OP | 49% | 65% | 101% | 557% | 100% | 112% | 97% | 95% |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 95 | 105 | 131 | 44 | 36 | 36 | 36 | 38 |
| Inventory Days | 69 | 52 | 77 | 184 | 182 | 158 | 200 | 175 |
| Days Payable | 126 | 110 | 182 | 211 | 163 | 184 | 221 | 206 |
| Cash Conversion Cycle | 38 | 48 | 27 | 17 | 55 | 10 | 14 | 7 |
| Working Capital Days | 67 | 81 | 86 | 16 | 30 | -2 | 9 | -15 |
| ROCE % | 30% | 27% | 1% | 29% | 25% | 31% | 33% |
| Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|
| Promoters | 69.00% | 69.00% | 69.00% |
| FIIs | 1.84% | 2.25% | 3.63% |
| DIIs | 6.77% | 7.02% | 12.90% |
| Public | 22.41% | 21.75% | 14.47% |
| No. of Shareholders | 31,035 | 19,609 | 20,185 |
Fundamentals
Market Cap₹ 12,712 Cr.
Current Price₹ 2,078
Stock P/E60.0
Book Value₹ 122
ROCE33.3 %
ROE29.5 %
Dividend Yield0.48 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)18%
Compounded Profit Growth (TTM)28%
Standalone figures.
Valuation
Market capRs 12,412 Cr
Enterprise valueRs 12,501 Cr
P/E (TTM)72.52x
Price to book25.85x
Price to sales9.24x
EV / EBITDA45.54x
EV / EBIT52.78x
EV / sales9.30x
Price to cash flow79.18x
Earnings yield1.38%
Dividend yield0.18%
Profitability
Operating margin (excl. other income)15.37%
Operating margin (incl. other income)15.89%
EBITDA margin20.43%
Pre-tax margin17.05%
Net profit margin12.74%
Net margin, latest quarter12.05%
ROE20.38%
ROCE24.72%
ROA12.70%
ROE, 3-year average14.50%
ROCE, 3-year average18.28%
ROA, 3-year average9.31%
ROE, 5-year average18.25%
ROCE, 5-year average22.29%
ROA, 5-year average11.92%
ROIC (approx.)31.79%
Tax rate23.62%
Other income / net worth1.10%
Growth
Sales growth (latest year)14.75%
Profit growth (latest year)6.85%
Sales CAGR, 3 years20.75%
Sales CAGR, 5 years14.77%
Profit CAGR, 3 years8.96%
Profit CAGR, 5 years21.11%
Sales growth QoQ-5.18%
Profit growth QoQ-20.90%
Sales growth YoY (latest quarter)15.03%
Profit growth YoY (latest quarter)-7.86%
Per share
EPS (TTM)Rs 27.98
EPS (latest year)Rs 14.80
EPS (latest quarter)Rs 6.74
EPS, 3-year averageRs 9.52
EPS, 5-year averageRs 61.20
Book value per shareRs 78.51
Sales per shareRs 219.72
Cash flow per shareRs 25.63
Free cash flow per shareRs 9.16
Dividend per share (latest year)Rs 3.70
Dividend per share, 3-year averageRs 3.23
Dividend per share, 5-year averageRs 3.23
Dividends
Dividend payout25.01%
Dividend payout, 3-year average22.50%
Dividend payout, 5-year average22.50%
Efficiency
Asset turnover1.22x
Fixed asset turnover2.64x
Inventory turnover2.43x
Inventory days150 days
Debtor days36 days
Debtors turnover10.15x
Creditor days206 days
Cash conversion cycle7 days
Working capital days-15 days
Leverage
Total debtRs 159 Cr
Cash and bankRs 70 Cr
Net debtRs 89 Cr
Debt to equity0.33x
Net debt / EBITDA0.32x
Interest coverage30.45x
Current ratio (filing 2026-03-31)0.96x
Quick ratio (filing 2026-03-31)0.62x
Trade payables (filing 2026-03-31)Rs 147 Cr
Owners' fund to total sources57.83%
Debt to assets19.14%
Cash flow
Cash from Operating Activity (latest year)Rs 157 Cr
Cash from Investing Activity (latest year)Rs -267 Cr
Cash from Financing Activity (latest year)Rs 99 Cr
Net Cash Flow (latest year)Rs -11 Cr
Free cash flow (latest year)Rs 56 Cr
FCFE (approx.: FCF + change in debt)Rs 187 Cr
Cash from ops / profit, 5 years1.53x
Sales to cash flow6.47x
Statement figures
Net sales (TTM)Rs 1,344 Cr
Net sales (latest year)Rs 1,014 Cr
Sales (latest quarter)Rs 342 Cr
Operating profit excl. other income (latest year)Rs 156 Cr
Operating profit (latest quarter)Rs 83 Cr
Other income (TTM)Rs -11 Cr
EBITDA (TTM)Rs 274 Cr
PBDT (TTM)Rs 267 Cr
Profit before tax (TTM)Rs 229 Cr
Tax (latest year)Rs 28 Cr
Net profit (TTM)Rs 171 Cr
Net profit (latest year)Rs 90 Cr
Net profit (latest quarter)Rs 41 Cr
Depreciation (TTM)Rs 38 Cr
Depreciation (latest quarter)Rs 9 Cr
Interest (TTM)Rs 8 Cr
Cost of goods sold (latest year)Rs 239 Cr
Total expenditure (latest year)Rs 859 Cr
Total income (latest year)Rs 1,020 Cr
Share capitalRs 61 Cr
ReservesRs 419 Cr
Shareholders' fundsRs 480 Cr
Total assetsRs 830 Cr
Net blockRs 384 Cr
Capital work in progressRs 121 Cr
InvestmentsRs 25 Cr
ReceivablesRs 100 Cr
InventoryRs 98 Cr
Other liabilitiesRs 191 Cr
Shares outstanding (crore)6.12
Ownership
Promoter holding69.00%
Computed by MarketFriction from the standalone statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | CORONA | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -3.9% | -2.8% | -1.1 pts |
| 1 month | -0.2% | -6.8% | +6.6 pts |
| 3 months | -0.4% | -7.6% | +7.2 pts |
| 6 months | +30.4% | +0.4% | +30.0 pts |
43 mutual fund schemes hold about ₹1,582 Cr.
Over three months 4 bought more and 17 sold (share counts, price move removed).
| Fund | Weight | Est. Cr | 3m shares |
|---|---|---|---|
| HDFC Flexi Cap Fund | 0.42% | 478 | -2% |
| Invesco India Smallcap Fund | 1.82% | 287 | -11% |
| Invesco India Midcap Fund | 0.90% | 144 | -9% |
| Invesco India Large & Mid Cap Fund | 0.89% | 105 | -6% |
| Aditya Birla SL ELSS Tax Saver Fund | 0.65% | 95 | +4% |
| Invesco India Multicap Fund | 1.26% | 57 | -1% |
| Union Small Cap Fund | 2.08% | 55 | +15% |
| Union Small Cap Fund | 2.08% | 50 | +15% |
| WOC Flexi Cap Fund | 0.40% | 36 | -6% |
| HDFC Pharma and Healthcare Fund | 1.07% | 36 | -17% |
| Kotak Business Cycle Fund | 0.95% | 33 | -1% |
| Edelweiss Recently Listed IPO Fund | 2.08% | 26 | +5% |
| Aditya Birla SL Pharma & Healthcare Fund | 2.17% | 23 | -4% |
| WOC Special Opp Fund | 1.17% | 23 | +1% |
| WOC Pharma and Healthcare Fund | 2.35% | 21 | -7% |
| WOC Multi Cap Fund | 0.47% | 19 | -8% |
| Invesco India ELSS Tax Saver Fund | 0.70% | 19 | -2% |
| Invesco India Consumption Fund | 2.65% | 16 | -1% |
| Kotak Consumption Fund | 0.65% | 11 | -3% |
| Kotak Healthcare Fund | 1.60% | 11 | -7% |
| Axis Equity Savings Fund | 0.91% | 8 | +3% |
| Union Multi Asset Allocation Fund | 0.42% | 4 | +0% |
| WOC Multi Asset Allocation Fund | 0.04% | 4 | -8% |
| Motilal Oswal Nifty Microcap 250 Index Fund | 0.13% | 3 | -3% |
| Union Business Cycle Fund | 0.55% | 3 | +5% |
Red flags
F-score 5 of 8| explain | Share dilution Share count up 0% in a year, 1230% in three |
| look | Auditor change Auditor change 2026-05-11: CORONA Remedies Limited has informed the Exchange regarding Change in Auditors of the company. |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Insider trades
NSE insider and takeover-code disclosures| Date | Who | Role | Side | Shares | Value | How |
|---|---|---|---|---|---|---|
| 2026-09-10 | Sage Investment Trust | Acquirer | sell | 51,641 | SAST Open Market | |
| 2026-09-10 | Anchor Partners | Acquirer | sell | 92,763 | SAST Open Market | |
| 2026-09-10 | Sepia Investments Limited | Acquirer | sell | 2,485,476 | SAST Open Market |
Latest disclosed trades by insiders, promoters and large holders. Grants, option exercises and pledges show as "other". A filing is a fact, not a signal on its own.
Latest quarter
Jun 2026Sales ₹422 Cr +21.6% vs Jun 2025.
Net profit ₹60 Cr +30.4%.
Against our estimate for Jun 2026: sales +3.6%, profit +13.3% beat. Our estimate for Sep 2026: sales Rs 436 Cr, profit Rs 59 Cr (how).
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2026-06-19 | Dividend - Rs 10 Per Share |
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Scrip PE is greater than 50 (4 trailing quarters)
Quick answers
What is the market cap of Corona Remedies Ltd?
Corona Remedies Ltd (CORONA) has a market capitalisation of Rs 12,712 Cr. at the 2026-10-01 close.
What is the P/E ratio of Corona Remedies Ltd?
Corona Remedies Ltd trades at a P/E of 60.0 on trailing twelve-month profit, at the 2026-10-01 close.
What were Corona Remedies Ltd's latest quarterly results?
In the Jun 2026 quarter, Corona Remedies Ltd sales was Rs 422 Cr (+21.6% vs Jun 2025) and net profit was Rs 60 Cr.
What is the 52-week high and low of Corona Remedies Ltd?
The 52-week high is Rs 2,292.40 and the 52-week low is Rs 1,336.60.